research Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
Low intensity ultrasound may reduce side effects of chemotherapy drugs like paclitaxel.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.
research Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
The treatment showed significant hair regrowth in alopecia areata patients without side effects.
research S100A4/Nonmuscle Myosin IIA/p53 Axis Contributes to Aggressive Features in Ovarian High-Grade Serous Carcinoma
S100A4 promotes aggressive ovarian cancer and is a potential treatment target.
research Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.
research Nitroxide pharmaceutical development for age-related degeneration and disease
Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
research 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
Rezpegaldesleukin shows promise for treating severe alopecia areata.
research 1P-230: Synthesis and in vitro characterization of 68 Ga labeled Fe 3 O 4 nanoparticles for drug delivery
The nanoparticles show promise for cancer treatment and diagnosis with fewer side effects.
research Synthesis and biological activity of raltitrexed-carrier conjugates.
Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
research Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy
Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
research Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma
Valproic acid helps delay hair loss and increases survival time for high-grade glioma patients undergoing radiation therapy.
research Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo
TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
research Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report
Ocrelizumab may cause total body hair loss in some patients.
research Sentinel lymph node in early stage ovarian cancer; a literature review
Sentinel lymph node mapping is safe and effective for early-stage ovarian cancer but isn't yet standard practice.
research Chemotherapy-Induced Alopecia
Imuvert can prevent some chemotherapy-induced hair loss.
research Trichodysplasia of immunosuppression treated with oral valganciclovir
Oral valganciclovir improved a patient's skin condition caused by immunosuppression.
research Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy
Immunochemotherapy successfully treated neutropenia in a patient with Waldenström's macroglobulinemia.
research Onabotulinum toxin A used to treat trichotillomania and trigeminal trophic syndrome
Onabotulinum toxin A may help treat trichotillomania and promote hair growth.
research 4‐octyl itaconate alleviates cisplatin‐induced ferroptosis possibly via activating the NRF2 /HO ‐1 signalling pathway
4-octyl itaconate may prevent hearing loss caused by the drug cisplatin by activating certain cell protection pathways.
research Tratamiento con tofacitinib en adolescentes con alopecia areata
Tofacitinib treatment is used for teenagers with alopecia areata.
research Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens
Improving treatment plans can reduce hair loss and improve life quality for ovarian cancer patients.
research 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
research Ivarmacitinib stimulates hair regrowth in severe alopecia areata
A phase 3 trial involving 330 adults with severe alopecia areata demonstrated that ivarmacitinib, a selective JAK1 inhibitor, significantly improved hair regrowth with a favorable safety profile. At week 24, 34.9% of participants in the 4 mg group and 40.6% in the 8 mg group achieved a SALT score of 20 or less, indicating at least 80% scalp hair coverage, compared to 9% in the placebo group. The treatment effect was statistically significant, with a 25.6% improvement for the 4 mg dose and 31.6% for the 8 mg dose over placebo. By week 52, those initially on placebo who switched to ivarmacitinib showed further improvement, with 47% in the 4 mg group and 63% in the 8 mg group achieving SALT20. The safety profile was consistent across groups, with no new safety concerns reported. These findings suggest ivarmacitinib as a promising and well-tolerated treatment option for severe alopecia areata.
research Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
research Chromatographic Method for Simultaneous Quantification of Gemcitabine and Olaparib Recovered from Isolated Pancreatic Tissue
A reliable method was developed to measure gemcitabine and olaparib in pancreatic tissue, aiding pancreatic cancer treatment.
research Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide
Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
research Cutaneous lupus erythematosus induced by tislelizumab
Tislelizumab can cause cutaneous lupus erythematosus.